Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202804 | 1.00 | HRH4 (0.48) | HRH4CA12CA1CA2CA7 | |
| SCHEMBL4570090 | 0.89 | HRH4 (0.51) | HRH4CA12CA1CA2CA7 | |
| SCHEMBL14185148 | 0.78 | ALDH1A1 (0.50) | SMN1; SMN2KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL3882151 | 0.78 | HRH4 (0.56) | HRH4CA12CA1CA2CA7 | |
| SCHEMBL3193640 | 0.78 | ALDH1A1 (0.67) | HRH4CA12CA1CA2CA7 | |
| SCHEMBL3209679 | 0.75 | L3MBTL1 (0.50) | HRH4SMN1; SMN2HPGDKMT2AL3MBTL1 | |
| SCHEMBL3209676 | 0.75 | L3MBTL1 (0.50) | HRH4SMN1; SMN2HPGDKMT2AL3MBTL1 | |
| SCHEMBL30204391 | 0.75 | HTT (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18842342 | 0.75 | HSD17B10 (0.50) | SMN1; SMN2HPGDKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL18816151 | 0.75 | HSD17B10 (0.50) | SMN1; SMN2HPGDKMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121602-B1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL) INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LTD (IN) | 2015-03-18 | — | — | EP | disclosed |
| US-20100041669-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041669-A1 | 4-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | HTR6, HTR5A, HTR1A | HRH4 340/4885CA12 4878/4885CA1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.